IL277333B1 - Vegf antagonists for use in treating diabetic macular edema - Google Patents
Vegf antagonists for use in treating diabetic macular edemaInfo
- Publication number
- IL277333B1 IL277333B1 IL277333A IL27733320A IL277333B1 IL 277333 B1 IL277333 B1 IL 277333B1 IL 277333 A IL277333 A IL 277333A IL 27733320 A IL27733320 A IL 27733320A IL 277333 B1 IL277333 B1 IL 277333B1
- Authority
- IL
- Israel
- Prior art keywords
- patient
- weeks
- vegf antagonist
- regimen
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
277333/ VEGF ANTAGONISTS FOR USE IN TREATING DIABETIC MACULAR EDEMA FIELD OF THE INVENTION The invention relates to methods for treating ocular disease with a VEGF antagonist. In particular, the invention relates to treating diabetic macular edema with less frequent dosing than currently approved treatment regimens.
BACKGROUND OF THE INVENTION Diabetes mellitus (DM) is the most common endocrine disease in developed countries, with prevalence estimates ranging between 2 to 5% of the world population. Diabetic retinopathy (DR) and diabetic macular edema (DME) are common microvascular complications in patients with diabetes and may have a debilitating impact on visual acuity (VA), eventually leading to blindness. DME is a frequent manifestation of DR (Riordan-Eva, 2004, Eye (Lond). 2004, 18:1161-8) and is the major cause of visual loss in patients with DR.
For anti-VEGF agents like ranibizumab or aflibercept a favorable benefit risk ratio was demonstrated with superior efficacy versus the previous standard of care (laser photocoagulation) in large Phase 3 programs that consequently led to their approval for the treatment of DME. Anti-VEGF treatment led to clinically relevant improvements of BCVA, reduction of fluid accumulation and decreased severity of diabetic retinopathy.
The current treatment options for patients with DME are: laser photocoagulation, intravitreal (IVT) corticosteroids, IVT corticosteroid implants, or IVT anti-VEGF therapeutic. Due to the efficacy and safety profile of anti-VEGF therapy, it has become the first-line treatment. Corticosteroids are used as a second line treatment and focal / grid laser photocoagulation remains a therapeutic option, but with a lower expected benefit compared with steroid and anti-VEGF therapy.
Despite the treatment success of existing anti-VEGFs, there remains a need for further treatment options to improve response rate and/or reduce resource use and injection frequency in patients with DME (Mitchell et al., 2011, Ophthalmology 118(4):615-25; Smiddy, 2011, Ophthalmology 118(9):1827–33; Lang et al., 2013, Ophthalmology 120(10):2004-12; Virgili et al., 2014, Br J Ophthalmol 98(4):421-2; Agarwal et al., 2015, Curr Diab Rep. 15(10):75).
Claims (8)
1. 277333/ CLAIMS 1. A VEGF antagonist for use in a method of treating diabetic macular edema (DME) in a patient, the method comprising: a) administering to the patient five individual 6 mg doses of brolucizumab at 6- week intervals, ending at week 24; b) administering to the patient additional doses of brolucizumab once every weeks (q8w regimen) starting at week 32, or once every 12 weeks (q12w regimen) starting at week 36; c) assessing the patient’s disease activity at weeks 32, 36, 48, 60, and 72, if disease activity is identified at any of the assessments, the patient is assigned to receive a q8w regimen, and d) at week 72 the patient’s q12w regimen can be extended by 4 weeks, to a q16w regimen, or the patient’s q8w regimen can be extended by 4 weeks, to a q12w regimen, if the patient’s disease activity is not worsening for multiple consecutive assessments, wherein the disease activity is assessed for relevant improvements of BCVA, reduction of central subfield thickness (CST), reduction of fluid accumulation, or decreased severity of diabetic retinopathy.
2. The VEGF antagonist for use according to claim 1, wherein if worsening of DME disease activity is identified after a q12w dose, the patient is switched to a q8w regimen, wherein the additional doses are administered once every 8 weeks instead of once every 12 weeks.
3. The VEGF antagonist for use according to claim 1, wherein if worsening of DME disease activity is identified after a q16w dose, the patient is switched to a q12w or q8w regimen, wherein the additional doses are administered once every 12 weeks or every 8 weeks instead of once every 16 weeks.
4. The VEGF antagonist for use according to claim 2 or 3, wherein the worsening of DME disease activity is a loss of letters in best corrected visual acuity (BCVA), increased central subfield thickness (CST), and/or increased fluid accumulation compared to any previous assessment. 277333/
5. The VEGF antagonist for use according to any one of claims 1-4, wherein the VEGF antagonist is administered by intravitreal injection.
6. The VEGF antagonist for use according to any one of claims 1-5, wherein the concentration of brolucizumab is about 60, 70, 80, 90, 100, 110, or 120 mg/ml.
7. The VEGF antagonist for use according to any one of claims 1-6, wherein each dose of the VEGF antagonist is 3 mg or 6 mg.
8. The VEGF antagonist for use according to claims 5-7, wherein each dose of the VEGF antagonist is administered as a 50 µL intravitreal injection.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862643887P | 2018-03-16 | 2018-03-16 | |
| US201962805344P | 2019-02-14 | 2019-02-14 | |
| PCT/IB2019/051899 WO2019175727A1 (en) | 2018-03-16 | 2019-03-08 | Methods for treating ocular diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL277333A IL277333A (en) | 2020-10-29 |
| IL277333B1 true IL277333B1 (en) | 2025-11-01 |
| IL277333B2 IL277333B2 (en) | 2026-03-01 |
Family
ID=66049363
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL277333A IL277333B2 (en) | 2018-03-16 | 2019-03-08 | Vegf antagonists for use in treating diabetic macular edema |
| IL323849A IL323849A (en) | 2018-03-16 | 2025-10-09 | VEGF antagonists for use in the treatment of diabetic macular edema |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL323849A IL323849A (en) | 2018-03-16 | 2025-10-09 | VEGF antagonists for use in the treatment of diabetic macular edema |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210017266A1 (en) |
| EP (1) | EP3765083A1 (en) |
| JP (3) | JP6938796B2 (en) |
| KR (2) | KR20260036043A (en) |
| CN (1) | CN111867631A (en) |
| AU (2) | AU2019235577B2 (en) |
| CA (1) | CA3091096A1 (en) |
| IL (2) | IL277333B2 (en) |
| MX (1) | MX2020009140A (en) |
| TW (1) | TWI727279B (en) |
| WO (1) | WO2019175727A1 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2828739T3 (en) | 2006-04-07 | 2021-05-27 | Aerpio Pharmaceuticals Inc | Antibodies that bind to human protein tyrosine phosphatase beta (HPTP-beta) and their uses |
| KR20180005753A (en) | 2008-06-25 | 2018-01-16 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | Stable and soluble antibodies inhibiting vegf |
| RU2653753C1 (en) | 2008-06-25 | 2018-05-14 | ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи | STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα |
| PL2307458T3 (en) | 2008-06-25 | 2018-08-31 | Esbatech, An Alcon Biomedical Research Unit Llc | Humanization of rabbit antibodies using a universal antibody framework |
| MX363351B (en) | 2011-10-13 | 2019-03-20 | Aerpio Therapeutics Inc | Methods for treating vascular leak syndrome and cancer. |
| WO2015200905A2 (en) | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| TWI806150B (en) | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | Stable protein solution formulation containing high concentration of an anti-vegf antibody |
| WO2017093969A1 (en) | 2015-12-04 | 2017-06-08 | Novartis Ag | Compositions and methods for immunooncology |
| IL290457B2 (en) | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and conjugates thereof |
| KR20190130608A (en) | 2017-03-22 | 2019-11-22 | 노파르티스 아게 | Compositions and Methods for Immune Oncology |
| CA3092588A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| MX2020009140A (en) * | 2018-03-16 | 2020-09-28 | Novartis Ag | Methods for treating ocular diseases. |
| EP3856245A4 (en) | 2018-09-24 | 2022-10-26 | EyePoint Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES TARGETING HPTP-ß (VE-PTP) AND VEGF |
| CN113194993A (en) | 2018-12-18 | 2021-07-30 | 诺华股份有限公司 | Protein solution formulations containing high concentrations of anti-VEGF antibodies |
| PE20240329A1 (en) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | DEVICES AND METHODS FOR PRECISION DOSE ADMINISTRATION |
| AU2020347575A1 (en) | 2019-09-13 | 2022-03-17 | Novartis Ag | Methods for treating ocular diseases |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CA3171563A1 (en) | 2020-03-25 | 2021-09-30 | Charles D. Blizzard | Ocular implant containing a tyrosine kinase inhibitor |
| WO2022066788A1 (en) * | 2020-09-23 | 2022-03-31 | Genentech, Inc. | Machine learning prediction of injection frequency in patients with macular edema |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| JP2026520094A (en) | 2023-04-11 | 2026-06-22 | オキュラ セラピューティクス,インコーポレイテッド | Ophthalmic implants including axitinib polymorphic IV |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160340420A1 (en) * | 2014-11-07 | 2016-11-24 | Novartis Ag | Stable protein solution formulation containing high concentration of an anti-vegf antibody |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1802334E (en) | 2004-10-21 | 2012-11-28 | Genentech Inc | Method for treating intraocular neovascular diseases |
| KR20180005753A (en) | 2008-06-25 | 2018-01-16 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | Stable and soluble antibodies inhibiting vegf |
| KR20180023015A (en) * | 2011-01-13 | 2018-03-06 | 리제너론 파아마슈티컬스, 인크. | Use of a vegf antagonist to treat angiogenic eye disorders |
| WO2014033184A1 (en) * | 2012-08-28 | 2014-03-06 | Novartis Ag | Use of a vegf antagonist in treating ocular vascular proliferative diseases |
| JP6959912B2 (en) * | 2015-09-23 | 2021-11-05 | ジェネンテック, インコーポレイテッド | Optimized variant of anti-VEGF antibody |
| MX2020009140A (en) * | 2018-03-16 | 2020-09-28 | Novartis Ag | Methods for treating ocular diseases. |
-
2019
- 2019-03-08 MX MX2020009140A patent/MX2020009140A/en unknown
- 2019-03-08 WO PCT/IB2019/051899 patent/WO2019175727A1/en not_active Ceased
- 2019-03-08 KR KR1020267006178A patent/KR20260036043A/en active Pending
- 2019-03-08 US US16/980,679 patent/US20210017266A1/en active Pending
- 2019-03-08 CN CN201980017221.0A patent/CN111867631A/en active Pending
- 2019-03-08 EP EP19715998.1A patent/EP3765083A1/en active Pending
- 2019-03-08 CA CA3091096A patent/CA3091096A1/en active Pending
- 2019-03-08 KR KR1020207028377A patent/KR20200131839A/en not_active Ceased
- 2019-03-08 IL IL277333A patent/IL277333B2/en unknown
- 2019-03-08 JP JP2020547357A patent/JP6938796B2/en active Active
- 2019-03-08 AU AU2019235577A patent/AU2019235577B2/en active Active
- 2019-03-14 TW TW108108562A patent/TWI727279B/en active
-
2021
- 2021-09-01 JP JP2021142541A patent/JP2021191778A/en not_active Withdrawn
- 2021-12-14 AU AU2021286278A patent/AU2021286278C1/en active Active
-
2023
- 2023-12-15 JP JP2023212445A patent/JP2024042697A/en not_active Withdrawn
-
2025
- 2025-10-09 IL IL323849A patent/IL323849A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160340420A1 (en) * | 2014-11-07 | 2016-11-24 | Novartis Ag | Stable protein solution formulation containing high concentration of an anti-vegf antibody |
Non-Patent Citations (2)
| Title |
|---|
| HEIER JEFFREY S ET AL,, INTRAVITREAL AFLIBERCEPT FOR DIABETIC MACULAR EDEMA 148-WEEK RESULTS FROM THE VISTA AND VIVID STUDIES, 17 September 2016 (2016-09-17) * |
| LALLY ET AL.,, VASCULAR ENDOTHELIAL GROWTH FACTOR AND DIABETIC MACULAR EDEMA. SURVEY OF OPHTHALMOLOGY, 26 October 2016 (2016-10-26) * |
Also Published As
| Publication number | Publication date |
|---|---|
| IL277333A (en) | 2020-10-29 |
| JP2021509912A (en) | 2021-04-08 |
| IL277333B2 (en) | 2026-03-01 |
| JP6938796B2 (en) | 2021-09-22 |
| IL323849A (en) | 2025-12-01 |
| EP3765083A1 (en) | 2021-01-20 |
| TWI727279B (en) | 2021-05-11 |
| AU2021286278B2 (en) | 2023-09-14 |
| WO2019175727A1 (en) | 2019-09-19 |
| KR20200131839A (en) | 2020-11-24 |
| TW201945027A (en) | 2019-12-01 |
| AU2021286278A1 (en) | 2022-01-20 |
| RU2020133816A (en) | 2022-04-18 |
| RU2020133816A3 (en) | 2022-04-18 |
| KR20260036043A (en) | 2026-03-13 |
| JP2021191778A (en) | 2021-12-16 |
| AU2019235577A1 (en) | 2020-08-27 |
| AU2021286278C1 (en) | 2024-05-23 |
| MX2020009140A (en) | 2020-09-28 |
| CA3091096A1 (en) | 2019-09-19 |
| US20210017266A1 (en) | 2021-01-21 |
| AU2019235577B2 (en) | 2021-09-30 |
| CN111867631A (en) | 2020-10-30 |
| JP2024042697A (en) | 2024-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL323849A (en) | VEGF antagonists for use in the treatment of diabetic macular edema | |
| Ishibashi et al. | The REVEAL study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema | |
| Sun et al. | Rationale and application of the protocol S anti–vascular endothelial growth factor algorithm for proliferative diabetic retinopathy | |
| Mitchell et al. | The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema | |
| Faghihi et al. | Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema | |
| Freund et al. | Intraocular pressure in patients with neovascular age-related macular degeneration receiving intravitreal aflibercept or ranibizumab | |
| Kourlas et al. | Ranibizumab for the treatment of neovascular age-related macular degeneration: a review | |
| Schmidt-Erfurth et al. | Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study | |
| Ciulla et al. | Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration | |
| Frampton | Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration | |
| JP2021004262A (en) | Treatment of age related macular degeneration with small active choroidal neovascularization lesion | |
| RU2572707C2 (en) | Ophthalmic drops with difluprednate for treating macular oedema | |
| Jiang et al. | Update on the use of anti-VEGF intravitreal therapies for retinal vein occlusion | |
| Shah et al. | Does laser still have a role in the management of retinal vascular and neovascular diseases? | |
| Özdek et al. | Posterior subtenon and intravitreal triamcinolone acetonide for diabetic macular edema | |
| Lightman et al. | Vision-related functioning outcomes of dexamethasone intravitreal implant in noninfectious intermediate or posterior uveitis | |
| JP6944958B2 (en) | Use of sirolimus for the treatment of exudative age-related macular degeneration with persistent edema | |
| Samanta et al. | Emerging therapies in nonexudative age-related macular degeneration in 2020 | |
| JP7176960B2 (en) | Salbutamol-containing ophthalmic medicine | |
| Heier et al. | Intravitreal combined aflibercept+ anti–platelet-derived growth factor receptor β for neovascular age-related macular degeneration: results of the phase 2 CAPELLA trial | |
| Tano et al. | EXTEND‐I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration | |
| Moon et al. | Intravitreal bevacizumab for macular edema from idiopathic juxtafoveal retinal telangiectasis | |
| Okhotsimskaya et al. | Aflibercept for the therapy of retinal diseases. A review of clinical studies | |
| Do | Antiangiogenic approaches to age-related macular degeneration in the future | |
| Yalcinbayir et al. | Intravitreal versus sub-tenon posterior triamcinolone injection in bilateral diffuse diabetic macular edema |